Insulin Degludec ELISA Kit

Catalog No.

KDB94004

Description

This assay employs the quantitative competitive enzyme immunoassay technique. An antibody specific for Insulin Degludec has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Insulin Degludec and then pipetted into the wells. Insulin Degludec in the sample competitively binds to the pre-coated antibody with biotin-labeled Insulin Degludec. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Insulin Degludec bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Insulin Degludec concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

781.25 - 50,000 ng/mL

Sensitivity

293.90 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	24965.8	6237.6	1673.1	27009.4	5933.5	1535.7
Standard deviation	1360.6	301.2	122.1	1801.3	274.5	181.5
CV (%)	5.5	4.8	7.3	6.7	4.6	11.8

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

NN1250, NN-1250

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta-Analysis., PMID:40509887

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353

Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D)., PMID:40469149

Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec., PMID:40465144

Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England., PMID:40441739

Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial., PMID:40318682

Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study., PMID:40309264

Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study., PMID:40258224

Exploring the Impact of Diabetes on Kidney Transplant: Patient Outcomes and Management Strategies., PMID:40255815

Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study., PMID:40236299

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine., PMID:40162894

Once-weekly Basal Insulin Fc versus daily insulin degludec for glycemic control in diabetes: a systematic review, meta-analysis, and meta-regression., PMID:40123989

A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes., PMID:40098469

Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes: The INHALE-3 Extension Study., PMID:40098468

Premixed insulin: Advantages, disadvantages, and future., PMID:40093285

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme., PMID:40083081

An overview of insulin therapy for the non-specialist., PMID:40035222

Once-Weekly Insulin Icodec Versus Once-Daily Insulin Degludec in Insulin-Naive Chinese Participants with Type 2 Diabetes: A Post Hoc Analysis of ONWARDS 3., PMID:40016570

In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec., PMID:40014293

No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6., PMID:39972508

Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial., PMID:39935080

Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers., PMID:39930729

Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes., PMID:39928225

How to improve the quality of euglycemic glucose clamp tests in long-acting insulin studies., PMID:39893469

Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer., PMID:39877434

Pharmacotherapy of type 1 diabetes - part 1: yesterday., PMID:39875200

Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs., PMID:39844001

Distribution-based sub-population selection (DSPS): A method for in-silico reproduction of clinical trials outcomes., PMID:39837001

Use of Degludec in Youth With Type 1 Diabetes and Recurrent Diabetic Ketoacidosis., PMID:39829694

Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study., PMID:39817213

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia., PMID:39802245

Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes., PMID:39786791

In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA1c but increased severe hypoglycemia at 26 wk., PMID:39761586

In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA1c at 52 wk., PMID:39761579

Newer Insulin Preparations and Insulin Analogs., PMID:39734941

Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study., PMID:39725356

Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis., PMID:39710291

Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China., PMID:39703112

Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus., PMID:39697865

Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study., PMID:39691971

A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes., PMID:39641970

Basal insulin analogues in type 1 diabetes - Does one size fit all? Lessons from the HypoDeg trial based on single-patient outcomes., PMID:39624290

Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study., PMID:39620193

Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross-sectional study., PMID:39588847

Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity., PMID:39566870

Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective., PMID:39525695

Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors., PMID:39533598

De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D)., PMID:39532398

Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study., PMID:39464932

Document Download

Insulin Degludec ELISA Kit.pdf